

TNO:

Initials:

Please complete this form prior to randomisation

This form must be completed by a trial investigator who has been delegated the responsibility of confirming patient eligibility

2.1 PARTICIPANT ELIGIBILITY

INCLUSION CRITERIA:

| | Yes | No |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|--------------------------|
| 1. Aged 18+ | <input type="checkbox"/> | <input type="checkbox"/> |
| 2. Female | <input type="checkbox"/> | <input type="checkbox"/> |
| 3. Diagnosis of ER positive invasive breast cancer, stages 1-3 and treated with curative | <input type="checkbox"/> | <input type="checkbox"/> |
| 4. Completed surgery for breast cancer | <input type="checkbox"/> | <input type="checkbox"/> |
| 5. Within 14 weeks of first oral adjuvant endocrine therapy (AET) prescription (tamoxifen or aromatase inhibitor) post breast cancer completion surgery | <input type="checkbox"/> | <input type="checkbox"/> |
| 6. Completed chemotherapy (if applicable) | <input type="checkbox"/> | <input type="checkbox"/> |
| <input type="checkbox"/> | | |
| 7. Able to access the internet | <input type="checkbox"/> | <input type="checkbox"/> |
| 8. Has access to an email address | <input type="checkbox"/> | <input type="checkbox"/> |
| 9. Are willing to use a support package with a web-based component. | <input type="checkbox"/> | <input type="checkbox"/> |

The following women will also be eligible providing they fulfil the above criteria:

Women undergoing , or planned to receive radiotherapy,

Women receiving anti-HER2 therapies,

Women receiving ovarian suppression drugs,

Women receiving, or planned to receive an adjuvant CDK4/6i (i.e abemaciclib)

EXCLUSION CRITERIA:

| | Yes | No |
|---------------------------------------------------------------------------------------------------|--------------------------|--------------------------|
| 1. Male | <input type="checkbox"/> | <input type="checkbox"/> |
| 2. Evidence of metastatic disease i.e. stage 4 disease (M1 regardless of T and N status) | <input type="checkbox"/> | <input type="checkbox"/> |
| 3. Previous adjuvant endocrine therapy (AET) for another previous breast cancer | <input type="checkbox"/> | <input type="checkbox"/> |
| 4. Have cognitive impairment sufficient to preclude participation, as judged by the clinical team | <input type="checkbox"/> | <input type="checkbox"/> |
| 5. Are unable to read and understand English | <input type="checkbox"/> | <input type="checkbox"/> |

TNO:

Initials:

2.2 CONFIRMATION OF ELGIBILITY

Is the participant eligible for randomisation?

Yes

No

Form completed by

Printed name:

Signature:

Date signed:

| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| d | d | - | m | o | n | - | y | y | y | y |
|---|---|---|---|---|---|---|---|---|---|---|

N.B. The individual named must be on the delegation log with the assigned responsibility for confirming eligibility.